The expression of the BCR-ABL fusion oncoprotein in primitive hematopoietic cells results in chronic myeloid leukemia. Over the past decade studies of several in vitro and in vivo cell systems revealed multiple signal transduction pathways activated by BCR-ABL. However, the precise function of BCR-ABL in the pathogenesis of CML is still unclear. The goal of this review is to synthesize data on intracellular signaling in the context of the diverse murine assay systems employed. We emphasize the importance of in vivo assays and assays using primary cells in understanding the biology of CML and the molecular mechanisms by which BCR-ABL exerts its effects.
Introduction
Chronic myeloid leukemia (CML), a biphasic, multilineage clonal hematopoietic disease, accounts for close to 20% of all leukemias. CML is caused by the reciprocal chromosomal translocation t(9,22)(q34;q11), the Philadelphia chromosome, in a primitive hematopoietic stem cell that results in formation of the fusion oncogene BCR-ABL. 1, 2 The product of BCR-ABL gene is usually a chimeric BCR-ABL protein of either 210 kDa or 190 kDa associated, respectively, with CML and acute lymphocytic leukemia (ALL). [2] [3] [4] [5] A much rarer third species of 230 kDa that may be preferentially associated with a milder form of CML has recently been identified. [6] [7] [8] [9] The CML stem cell generates a dominant multilineage clone which overproduces all hematopoietic progenitors (colony-forming cells, CFCs) as well as more differentiated granulocytes. During the chronic phase of CML increased numbers of hematopoietic progenitors and granulocytes are found in the peripheral blood, and patients often exhibit a massive splenomegaly and a mild anemia. 10 The CML chronic phase, generally 3 to 6 years, progresses inevitably to blast crisis during which the acquisition of secondary mutations impede normal differentiation and results in accumulation of undifferentiated blasts. Mice transgenic for BCR-ABL or repopulated with bone marrow cells that were infected with BCR-ABL cDNA developed leukemia, establishing the direct role of BCR-ABL in inducing leukemia. 11, 12 Though using murine model systems the role of BCR/ABL in CML has been well-dissected at the molecular level, several key questions remain puzzling and worthy of redoubled efforts at explanation. Given that BCR/ABL is responsible for the dramatic hyperplasia of hematopoietic progenitors, both myeloid and erythroid, how does one explain the striking Correspondence: S Ghaffari, Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA, 02142, USA; Fax: 617 258 6768 Received 18 December 1998; accepted 9 April 1999 granulocytic predominance that defines the disease? What aspects of cytokine regulation are subverted by BCR/ABL, and which cytokine signals cooperate to expand the myeloid lineage? What role does BCR/ABL play in promoting proliferation vs encouraging enhanced cell survival? And how are we going to integrate all of the complex data gleaned from in vitro assays into a comprehensive mechanism for induction of leukemia by BCR/ABL, a model that predicts how best to intervene therapeutically against critical targets? Although some of these questions could be answered using human CML cells, murine model systems have been invaluable in dissecting BCR-ABL signaling at a molecular level. The goal of this review is to synthesize the abundant array of data from mouse experiments on the complex signaling pathways affected by BCR/ABL, and to point out that the extensive mutational analysis of BCR/ABL domains that activate various signal transduction proteins has to be interpreted in the proper context of specific assays and cell types employed. Fortunately, novel murine models of CML that have a greatly enhanced efficiency of disease induction are now available 13, 14 and promise to provide a better means of assessing the true impact of BCR/ABL mutations and signaling pathways on the most critical assay of all: leukemia induction.
Cytokine pathways in CML
In CML patients there is a parallel increase in granulocytic and erythroid progenitors in peripheral blood. Despite the major increase in granulopoiesis it has been difficult to demonstrate any abrogation of growth factor requirement for granulocyticmacrophage progenitors in vitro. In contrast, in vitro proliferation and differentiation of erythroid progenitors from CML patients in the absence of erythropoietin or other cytokines has been observed. 15 The presence of Steel Factor may also be required for this effect. 16 We showed that P210 BCR-ABL can functionally replace the erythropoietin receptor (EpoR) and support full proliferation, differentiation and maturation of fetal liver erythroid progenitors from EpoR −/− mice. P210 BCR-ABL can also partially complement myeloid growth factors that are normally required in addition to Epo for erythroid development. 17 These results demonstrate that P210 BCR-ABL can induce differentiation of at least one type of hematopoietic progenitor; they are also consistent with the notion that terminal differentiation of erythroid cells does not require a unique signal emanating from the Epo receptor.
Despite the ability of CML erythroid progenitors to grow in the absence of Epo in culture, in CML patients there is a mild decrease, rather than an increase, in the number of mature erythrocytes. The molecular mechanism underlying this phenomenon is unknown. Nor do we know why BCR-ABL causes the expansion of multiple lineage-restricted clonogenic cells but causes a specific elevation only in the numbers of granulocytes and, to a lesser extent, platelets. How and why does BCR-ABL cause multilineage CML cells to differentiate into lineage restricted clonogenic cells?
In order to understand the molecular mechanism of expansion of myeloid cells in CML, many investigators have focused on identification of signal transduction pathways activated by BCR-ABL, characterizing their importance for cell transformation and identifying the BCR-ABL domains involved. Given the increased number of differentiated granulocytes, an initial focus has been the identification of cytokine signal transduction pathways that are activated by BCR-ABL and that may support proliferation and/or differentiation of myeloid progenitors. Indeed, BCR-ABL activates many signaling pathways including Ras/MAPK, JAK and STATs, JNK, PI3-Kinase, Myc, Cyclin D, NF-b, AKT and Bcl2. Also, many proteins are found in immunocomplexes with BCR-ABL, including cytoskeletal and focal adhesion proteins, BCR, CRKL and Cbl, and thus may be activated by this oncoprotein (reviewed in Refs 18 and 19).
Domain structure of the chimeric BCR-ABL oncoprotein
BCR-ABL is generated by a chromosomal translocation that fuses BCR gene sequences to a segment upstream of the second c-Abl exon. genes is a constitutively active tyrosine kinase that is several hundred-fold more active than the c-ABL protein tyrosine kinase; the kinase activity of P190 BCR-ABL is about five-fold more than that of P210 BCR-ABL22 as measured in Rat-1 fibroblasts cells transformed by BCR-ABL. While c-ABL is essentially a nuclear protein, most BCR-ABL is localized to the cytoplasm. 23 As noted, a third BCR-ABL species, P230
BCR-ABL , that contains a BCR exon 19/ABL exon 2 junction has been identified, but it is not well characterized at the molecular level. [6] [7] [8] [9] P190
BCR-ABL and P210 BCR-ABL contain similar ABL sequences, including an autophosphorylation site within the kinase domain, an SH3 and an SH2 domain that regulate kinase activity, a nuclear transport domain, a DNA binding domain, and at the very C-terminus an actin binding domain ( Figure 1 ). P190 BCR-ABL and P210 BCR-ABL also contain similar BCR segments, including a 63 amino acid domain at the very N-terminus, the oligomerization domain, that is thought to activate ABL kinase activity by bringing two kinase domains into proximity and allowing one to phosphorylate and activate the other. 24 Both BCR-ABL fusion proteins also contain two BCR SH2-binding domains (amino acids 176-242 and amino acids 298-413) that overlap with the BCR serine threonine kinase domain. [25] [26] [27] Both BCR-ABL oncoproteins lack the carboxyterminal region of BCR that is homologous to a GTPase activating protein (GAP) and which has GAP activity towards the Rac GTP binding protein.
P190
BCR-ABL lacks some additional carboxy-terminal sequences of BCR that are found in P210 BCR-ABL . This BCR region corresponds to a Dbl homologous domain 29 which has GTP-GDP exchange factor activity for members of the Rho family of GTP-binding proteins 30 and a PH domain. 29 It is unknown whether the presence of the Dbl homology domain in P210
BCR-ABL has any effect on its tyrosine kinase activity or transformation ability.
BCR-ABL signaling and transformation are cell and assaydependent
In reviewing the transforming potential of BCR-ABL proteins, it is important to bear in mind the nature, specificity, and limitations of the assays used. Many in vitro and in vivo assays have been used to assess the oncogenicity of BCR-ABL and its various mutated or truncated forms: focus-formation and abrogation of contact inhibition in Rat1 fibroblasts; anchorage-independent growth of transformed Rat1 cells, as judged by colony formation in soft agar; cytokine-independent growth of hematopoietic cell lines; proliferation of bone marrow lymphoid progenitors in culture; and tumor formation by BCR-ABL-expressing growth factor-independent or -dependent cells in nude mice. 31, 32 Most of this work has employed P190 form of BCR-ABL that is associated with Ph + ALL and not the P210 form associated with CML. Many of the signaling pathways activated by BCR-ABL have been identified in transfected fibroblast lines, not in hematopoietic cells. The crucial importance of cellular context for both the transformation capacity of BCR-ABL mutants and the downstream signaling pathways activated by BCR-ABL has recently become evident. In fact, the variability in the degree of transformation achieved by BCR-ABL and its mutants appears to depend on both the cellular context and the specific assay used (Table 1) .
BCR-ABL expression and growth factor independence of primitive hematopoietic CML cells
Expression of BCR-ABL can allow factor-independent growth of cell lines that normally require cytokines such as IL-3, GM-CSF, IL-7 or erythropoietin for their proliferation and survival. 33, 34 Although the term factor-independent is used, such cells are always cultivated in serum and thus are invariably stimulated by growth factors such as insulin and PDGF.
Further, all such cell lines have probably accumulated one or more oncogenic mutations, and thus their requirement for growth factors to prevent apoptosis or support proliferation may not be the same as for the corresponding cell type in vivo.
Although BCR-ABL can render cell lines growth factor-independent, CML granulocytic-macrophage progenitors require growth factors for their proliferation and differentiation in culture. In agreement with this observation, expression of BCR-ABL in multipotent hematopoietic progenitors induces growth factor independent proliferation and differentiation only after a long period of in vitro culture and does not render these cells leukemogenic in mice. 35 Recent observations suggest that primitive CML cells may grow in culture in the absence of growth factors and differentiate rapidly into granulocytes and macrophages because of an autocrine production of IL-3, GM-CSF and/or G-CSF 14 by primitive but not mature hematopoietic cells. 36 These findings are supported by earlier observations indicating that BCR-ABL-transformed 'immature' myeloid murine FDCP1 cells produced small amounts of cytokines, whereas the more 'differentiated' Pro-B Ba/F3 cells transformed by BCR-ABL did not. 33, 37 The biology of CML also indicates that BCR-ABL has different functions and outcomes depending on the cell in which it is expressed. BCR-ABL may provide a proliferative signal to a lineage-restricted clonogenic cell but induce differentiation of a primitive multilineage hematopoietic cell under the same growth factor conditions which results in the proliferation of its normal counterpart. 38 In addition to abnormal proliferation and cycling, CML primitive hematopoietic cells exhibit abnormal adhesion to stroma and abnormal migration on extracellular matrix proteins. Although many signaling pathways activated by BCR-ABL have been identified, it is still unclear how the activation of any of these pathways may contribute to the abnormal proliferation, survival, adhesion, or migration that characterizes primitive CML hematopoietic cells. Understanding of BCR-ABL signaling in primary cells and in vivo is a principal challenge of the next 10 years.
Domains in BCR-ABL important for transformation
BCR-ABL is a constitutively active protein tyrosine kinase. As assessed by all of the transformation assays listed above, the tyrosine kinase activity of BCR-ABL is essential to its oncogenic potential 22 (see Table 1 ). The oligomerization domainthe N-terminal 63 amino acids of BCR and BCR-ABL -is essential for the high and constitutive BCR-ABL tyrosine kinase activity. 24, 39, 40 The oligomerization domain is the only BCR domain required for growth factor independence of BCR-ABL transformed hematopoietic cells, but both the oligomerization domain and residues 176-242 of BCR are necessary for BCR-ABL transformation of fibroblasts. 24 Within amino acids 176-242 are sequences that bind SH2-containing peptides. 26, 41 This region includes tyrosine Y177 which, when phosphorylated, provides a docking site for the Grb-2 SH2 domain, leading to activation of the Ras pathway. 41 The SH3 domain of BCR-ABL apparently negatively affects ABL tyrosine kinase activity. 42 Deletion of the SH3 domain from BCR-ABL mutants lacking the oligomerization domain partially restores growth factor-independence to Ba/F3 cells. 43 J Wang and colleagues have formulated a model proposing that oligomerization of BCR-ABL sequesters the SH3 domain and prevents it from negatively regulating the ABL tyrosine kinase. 24 The SH3 domain may contribute to BCR-ABL leukemogenesis by reducing the ability of BCR-ABL-transformed cells to adhere to certain extracellular matrices; 44 deletion of the SH3 domain also resulted in a decrease of the ability of BCR-ABL-transformed bone marrow cells to home after injection into mice. 44 The ABL kinase regulatory domain possesses a tyrosine (Y1294) which is the major auto-phosphorylation site in BCR-ABL. 45 By analogy to other protein tyrosine kinases, this tyrosine is expected to be in the 'activation loop' which physically blocks the kinase catalytic site. Phosphorylation of this tyrosine would be expected to cause the loop to swing out of the catalytic site and thus activate kinase activity. While mutation of this tyrosine to phenylalanine does decrease the ability of BCR-ABL to transform fibroblasts, it does not alter BCR-ABL tyrosine kinase activity. Thus, the exact function of Y1294 is unclear.
The ABL SH2 domain is also important for BCR-ABL transformation of fibroblasts 25 but apparently has no direct effect on BCR-ABL tyrosine kinase activity. 46 The Grb-2-binding site (Y177F) is also essential for BCR-ABL transformation of fibroblasts. Importantly, as judged by expression of single BCR-ABL point mutants, neither the major auto-phosphorylation site (Y1294) nor the ABL SH2 domain nor the Grb-2-binding site (Y177F) are essential for BCR-ABL to confer cytokineindependent growth to growth factor-dependent hematopoietic cell lines or to transform lymphoid progenitors in culture. 32, 46 In fact, the absence of the ABL SH2 domain in BCR-ABL increases its transformation potential in hematopoietic cells and enhances the growth factor-independent proliferation of hematopoietic cells. 23 , 47 A triple BCR-ABL mutant lacking Y177, Y1294, and the ABL SH2 domain is still able Properties of selected published BCR-ABL mutants are shown. The specific tyrosine kinase activity is depicted by −; equivalent or less than c-ABL tyrosine kinase activity; or +; equivalent or higher than P210 tyrosine kinase activity. a Tyrosine kinase activity of P190 is at least five-fold higher than P210. Transformation by individual mutants is assessed by suppression of contact inhibition-growth in a Rat-1 focus formation assay, abrogation of anchorage-dependent growth in a Rat-1 soft agar colony formation assay; propagation of lymphoid cells in long-term bone marrow (BM) cultures; or tumor formation of growth factor-independent BCR-ABL-infected cells in vivo (BM to confer factor-independent proliferation to Ba/F3 cells, though it is unable to confer growth factor independence to 32D cells. 46 Thus, even among hematopoietic cell lines there are significant differences in requirements of specific segments of BCR-ABL for factor-independent growth.
In addition to regulating the tyrosine kinase activity of BCR-ABL, the N-terminal oligomerization domain is essential for increasing the actin-binding activity of the ABL carboxy-terminal region. 23 The ABL actin-binding domain is important for BCR-ABL transformation of fibroblasts 23 and BCR-ABL mutants defective in actin binding exhibit some reduction in their ability to abrogate IL-3 independence in Ba/F3 cells. The role of the actin binding segment of BCR-ABL in conferring growth factor-independence to transformed cells is not clear. In particular, we do not know whether binding of BCR-ABL to actin filaments is required to bring certain enzymes and their specific substrates together, or whether concentration of BCR-ABL in certain subcellular locations is critical for activating cytoskeletal proteins.
Recent experiments established that, depending on the cell in which BCR-ABL is expressed, multiple domains of BCR-ABL may contribute to the activation of the same intracellular signal transduction pathway. 32, 46 For example, in cells expressing a mutant BCR-ABL (Y177F) which lacks the tyrosine residue required for Grb-2 binding and is therefore presumed to be unable to activate the Ras pathway, Ras is still activated through direct tyrosine phosphorylation of Shc. Shc then binds Grb-2 and stimulates formation of the Grb-2-Sos complex and thus activation of Ras. 32, 46 While hematopoietic cells expressing the mutated BCR-ABL (Y177F) are transformed, as assessed by growth factor-independent proliferation, fibroblasts are not transformed by this mutant BCR-ABL. Apparently expression of BCR-ABL (Y177F) in fibroblasts does not result in Shc phosphorylation and activation, another difference in the response of fibroblasts and hematopoietic cells to BCR-ABL. Interestingly, overexpression of Shc in fibroblasts complements for transformation by BCR-ABL (Y177F). 32 Thus hematopoietic cells but not fibroblasts allow multiple domains of BCR-ABL to activate the same or equivalent downstream signaling pathways. This may explain why the tyrosine kinase and oligomerization domains of BCR-ABL are the only ones essential for growth factor-independence of hematopoietic cells. Similarly, signaling molecules recruited and activated by the EpoR include JAK2, STAT5, Grb2, SHC, Ras, Raf and MAP kinase, the phosphatases SHP1 and SHP2 and SHIP, PKC, PI-3 kinase and PLC-␥. 48 Mutant EpoRs capable of activating only a subset of these signal transduction proteins, for instance only STAT5 or only PI-3 kinase, are capable of supporting normal in vitro differentiation of primary erythroid progenitors from EpoR −/− mice. [49] [50] [51] [52] [53] Thus, many of the signaling pathways activated by the EpoR appear redundant. None of these signal transduction proteins are unique to the EpoR and most are activated by a large number of other cytokine receptors as well as BCR-ABL and other types of growth factor receptors.
Taken together, these findings emphasize the importance of understanding of BCR-ABL signaling in the context of primary cells and in animals, in addition to cultured cell lines. The establishment of an in vivo animal model of CML has been a focus of many investigators. Although initial attempts were extremely valuable, in that they directly demonstrated that BCR-ABL expression generated CML by transforming a primitive hematopoietic cell, the experiments were too inefficient for routine analyses. 11, 12 Recently, two groups established a very efficient and reproducible murine in vivo model for CML by using advanced gene transfer technologies; these systems promise to elucidate the role(s) of different BCR-ABL domains and signaling pathways in induction of leukemia. 13, 14, 54 In vivo transplantation experiments using BCR-ABL-transduced primitive hematopoietic cells from knock-out mice in which a gene which encodes for a specific cytokine, cytokine receptor or adhesion molecule has been deleted should generate valuable information regarding the pathogenesis of CML. Although differences between the human and murine disease will still persist, it may in the future be possible to use these mice to test novel therapeutic agents.
Does BCR-ABL induce proliferation or just survival?
Recent studies suggest that the specificity of lineage-restricted cytokines such as Epo, thrombopoietin, and G-CSF is a result of the unique expression pattern of each receptor by progenitors of a given lineage. 55 Cytokine receptor expression is the result, rather than the cause, of lineage commitment; it allows specific cytokines to selectively rescue and amplify progenitors of a particular lineage according to physiological need. The unique outcome of cytokine receptor signaling is a result of the unique cellular environment in committed progenitors. Differentiation of committed progenitors apparently proceeds along a predetermined program, supported by cytokine receptor-activated 'generic' signals common to many cytokine receptors.
A similar question can be asked of the growth factor-independence conferred by BCR-ABL to myeloid cell lines. Does BCR-ABL send signals specifically inducing the proliferation of certain hematopoietic cells, or does it only support the survival of cells in which it is expressed? Recent observations suggest that BCR-ABL-induced growth factor independence is secondary to the suppression of apoptosis and not an immediate consequence of BCR-ABL expression. 56 By expressing a temperature-sensitive BCR-ABL mutant in IL-3-dependent Ba/F3 cells, Kabarowski and colleagues 56 showed that growth factor-independence occurs only after long exposure to BCR-ABL expression. While activation of ERK2 MAP kinase occurs as an immediate response to IL-3 activation, activation of ERK2 is secondary to growth factor-independent growth of cells expressing BCR-ABL and is not directly linked to the expression of BCR-ABL per se.
At least some of the anti-apoptotic effects of BCR-ABL may be supported by activation of the Ras pathway 46 since Ras activates anti-apoptotic but not mitogenic pathways in IL-3 or GM-CSF responsive cells. 57 Mutant forms of the common ␤ C subunit of the IL-3 and GM-CSF receptor that are not capable of Ras activation can still support DNA synthesis. However these mutants failed to prevent apoptosis, supporting the importance of Ras activation in preventing apoptosis in these cells. In addition, expression of an activated Ras in hematopoietic cell lines blocked apoptosis upon growth factor deprivation. 57 As indicated previously, a BCR-ABL deletion mutant (BCR-ABL ⌬176-427) missing the tyrosine 177 Grb-2-binding site 41 can nonetheless activate the Ras pathway in 32D cells, possibly through phosphorylation of Shc. 32 Unlike parental 32D cells, 32D cells expressing BCR-ABL ⌬176-42 became resistant to apoptosis in the absence of IL-3. However, in agreement with the findings on mutant common ␤ C subunits unable to activate Ras, the mutant BCR-ABL ⌬176-42 did not support significant proliferation or mitogenesis of 32D cells. 46 BCR-ABL may exert some of its anti-apoptotic effect through the activation of STAT transcription factors. 58 By comparing the intracellular signal transduction molecules activated in clones of Ba/F3 cells expressing either BCR-ABL or the constitutively active EpoR (R129C), 59 it was shown that both proteins induce growth factor-independent proliferation but only BCR-ABL and not EpoR (R129C) can confer resistance to apoptosis upon serum deprivation or addition of apoptosisinducing agents. This anti-apoptotic effect of BCR-ABL correlated with activation of STATs and not with the levels of the anti-apoptotic proteins Bax and Bcl2, the levels of which were the same in cells expressing either BCR-ABL or EpoR (R129C). 58 However, we do not know which anti-apoptotic pathways might be activated by STAT proteins.
BCR-ABL expression abrogates anchorage-dependent but not growth factor-dependent proliferation of 3T3 cells. 60 Like v-ABL, BCR-ABL can transform a subset of 3T3 cells and form colonies in soft agar. However, 3T3 cells transformed by BCR-ABL cannot grow in low serum, in contrast to 3T3 cells transformed by v-ABL. The ability of serum to activate mitogenesis of 3T3 cells requires that they be anchored to an extracellular matrix; similarly, the activation of the Jun transcription factor by serum requires that 3T3 fibroblasts be attached to a culture plate. As measured by reporter gene assays, expression of BCR-ABL in 3T3 cells can alleviate the anchorage requirement for serum activation of the Jun promoter. Although it is not clear what pathways are involved, activation of Ras by BCR-ABL does not seem to be responsible for this effect. 60 Both the oligomerization domain and sequences within amino acids 176 to 242 are required for BCR-ABL to confer anchorageindependent growth to 3T3 cells. An important unanswered question is whether anchorage-independent growth of BCR-ABL-expressing 3T3 cells is caused by the same molecular mechanism as growth of CML cells independent of attachment to the bone marrow stroma. In particular, we do not know whether stromal adhesion defects seen in Ph + primitive hematopoietic cells from CML patients are directly related to their increased proliferation. [61] [62] [63] Perspectives for the future While we have learned a great deal about signal transduction pathways activated by BCR-ABL, we have also learned that different primary cells and cultured lines of hematopoietic cells and fibroblasts respond differently to BCR-ABL; some respond by proliferation in the absence of growth factors, others by anti-apoptosis, and yet others by differentiation. Other factors such as the level of BCR-ABL expression and the balance of intracellular signaling pathways that are activated may affect the cellular response.
Importantly, the effects of BCR-ABL expression may vary in CML cells at distinct stages of the disease, possibly correlating with the extent of 'differentiation' or other oncogenic mutations that may have occurred. BCR-ABL may confer survival to a very primitive hematopoietic stem cell but induce proliferation or differentiation, depending on the cellular lineage, in more differentiated cells. For example the effects of BCR-ABL expression on neutrophil function are not clearly known. BCR-ABL is missing the Rac-GTPase containing domain of BCR. Also, neutrophils in both BCR −/− and Rac2 −/− mice exhibited similar increases in the production of reactive oxygen metabolites. 64, 65 Thus, one could imagine that BCR-ABL-expressing CML neutrophils may exhibit some alterations in this function as well.
In addition, recent work suggests that the amount and type of cytokine produced varies considerably depending on the type of progenitors expressing BCR-ABL; 36 this may also contribute to the different in vivo effects seen after expression of BCR-ABL in different progenitors. The challenge for the future is to determine the responses to BCR-ABL expression in the primitive hematopoietic stem cell and in several types of hematopoietic cells at distinct stages of differentiation. It is also crucial to pinpoint the relevant domains of BCR-ABL responsible for various functions in order to design novel therapeutic molecules.
